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ter study
Huu Tri Bui (1), Coralie Barbe (2), Pierre Nazeyrollas (3), Amine Hadj-
Henni (1), Damien Metz (3), Anne Long (1)
(1) Hôpital Robert Debré, CHU Reims, Medecine Vasculaire, Reims,
France – (2) CHU Reims, Centre de Recherche d’Investigation Clinique
et d’Aide Méthodologique, Reims, France – (3) Hôpital Robert Debré,
CHU Reims, Cardiologie, Reims, France
Background: Common risk factors for coronary heart disease (CHD) and
abdominal aortic aneurysm (AAA) are mainly male gender, past or current
smoking and older age. But little is known about AAA prevalence in this well-
defined population. The aim of this prospective study was to evaluate the prev-
alence of AAA in patients presenting with an acute coronary syndrome and
coronary stenosis ≥ 50% at coronarography.
Material and methods: Between February 2008 and March 2009, 306
patients hospitalized for an acute coronary syndrome (unstable angina, Q-wave
myocardial infarction or non Q-wave myocardial infarction) gave informed
consent for AAA ultrasound (US) screening. Maximal anteroposterior longitu-
dinal and transverse diameter were measured. AAA was considered if at least
one diameter was equal or exceeded 30 mm. Risk factors for cardio-vascular
disease and coronary status were prospectively collected. Characteristics of
patients with or without AAA were compared using Khi2 or Fisher test as
appropriate if variables were qualitative and using Wilcoxon test if variables
were continuous.
Results: Among 304 patients with reliable US (feasibility 99.4%), preva-
lence of AAA was 6,6% (20/304). Prevalence tended to increase in patients
older than 50 years (p = 0.09). No AAA was detected in patients less than 50
years. Prevalence reached 7,7 % (20/260) in patients > 50 years, 7.4 % (13/
176) in patients > 60 years and 9,6 % (11/114) in patients > 70 years. Previous
coronary events were more frequent in patients with AAA (p = 0.02). In men
older than 50 years, current or past smokers with previous coronary events,
prevalence raised to 13% (8/63).
Conclusion: Prevalence of AAA in patients with acute coronary syndrome
and coronary stenosis ≥ 50% was 6,6% in this study ; furthermore, screening
seemed particularly interesting in men aged more than 50 years, smoker with
personal history of coronary disease, because of a prevalence more than 10%.
281
Prevalence of peripheral Arterial disease in subjects with a moderate
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Background: Symptomatic or asymptomatic peripheral artery disease
(PAD) is a strong marker of cardiovascular events and Death. The prevalence
of PAD is well documented in a high-risk subset, but less information is avail-
able in patients with moderate or intermediate CV risk.
Objective: To assess the prevalence of asymptomatic PAD defined as an
ABI≤0.9 in subjects with moderate cardiovascular (CV) risk.
Methods: PANDORA is a multicentre, international, cross-sectional obser-
vational study performed in primary care. ABI measurement was performed in
subjects with > 2 CV risk factors (RF) with no overt vascular disease nor dia-
betes mellitus.
Results: Among 10287 subjects in Europe, 1011 were included in France.
The mean age is 65 yrs (males 55%). ABI≤0.9 was found in 12.2% (95%CI
[10.1;14.2]). Mean LDL-cholesterol was 1.29 g/L. Results for RF association
(Logistic regression) are shown in table 1.
Table. 
Conclusion: In the Pandora study, the prevalence of asymptomatic PAD
among subjects with moderate CV risk in France is 12.2%, strongly related to
smoking and low physical activity. In patients with moderate CV risk, detec-
tion of asymptomatic PAD and management of modifiable RF such as
smoking and physical activity could improve the overall CV risk. PANDORA
Study was sponsored by AstraZeneca.
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Purpose: The beneficial effect of lipid-lowering drugs on cardiovascular
mortality is well established, but long term safety data remain scarce. The aim
of this study was to assess 10-year risk of cancer mortality according to blood
lipid levels and lipid-lowering drug exposure, in the French general popula-
tion.
Methods: Our analysis was based on the Third French MONICA Cross-
sectional survey on cardiovascular risk factors (1995-1996). Participants aged
35-64 years were randomly recruited from French polling lists. Subjects with
a history of cancer at baseline were excluded from the analysis. Vital status
and cause of mortality were obtained 10 years after inclusion.
Results: There were 3262 participants and 177 deaths were recorded (78
due to cancer). The sample was mainly composed of subjects in primary car-
diovascular prevention (96%) and comprised 64% of normolipidemic, 25% of
untreated dyslipidemic (total cholesterol ≥ 6.5 mmol/L or triglycerides ≥ 3.5
mmol/L) and 11% of dyslipidemic subjects treated with a lipid-lowering drug
(4% statin, 6% fibrate). After adjustment for centre, age, smoking, gamma-
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 Chi2 p-value OR 95%CI
Age 0.705 1.004 0.982-1.027
Gender (male vs female) 0.982 1.006 0.600-1.686
BMI 0.325 0.972 0.916-1.029
Family history of premature CHD 
(yes vs no)
0.744 1.133 0.534-2.405
HDL-C (low vs not low) 0.898 1.039 0.577-1.872
LDL-C (High vs not high) 0.427 0.847 0.562-1.276
Sitting BP (hypertension vs normal BP) 0.071 1.598 0.961-2.657
Smoking status (Habitual smoker 
vs non-smoker)
0.012 2.017 1.166-3.489
Physical activity (inactive vs active) 0.0003 2.144 1.414-3.250
Alcohol (high intake vs no intake) 0.845 0.927 0.433-1.984
Statin treatment (Treated vs Untreated) 0.101 0.601 0.329-1.104
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glutamyl transpeptidase and mean corpuscular volume, which were all signif-
icantly associated with cancer mortality, the hazard ratio (HR) for cancer mor-
tality in subjects with non HDL-cholesterol < 3.5 mmol/L was 2.83 [95%
confidence interval: 1.73-4.62]. The adjusted HR in subjects with HDL-cho-
lesterol < 0.9 mmol/L was 2.87 [1.63-5.06]. The adjusted HR in subjects on
lipid-lowering drug as compared to untreated subjects was 0.31 [0.11-0.85].
Conclusion: In this cohort mainly composed of primary prevention sub-
jects, low HDL- and low non HDL-cholesterol levels were associated with
increased cancer mortality, whereas risk of cancer death was reduced in users
of lipid-lowering drugs. This suggests that the impact of low cholesterol on
cancer risk may be different in subjects with spontaneously low levels and in
those for whom cholesterol is lowered by lipid-lowering drugs.
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Introduction: Regular light to-moderate wine consumption, defined as 1–
3 drinks/day, is associated with a lower risk of cardiovascular disease. More-
over, half of the cardiovascular benefit of wine consumption would be attrib-
utable to its High density lipoprotein-cholesterol (HDL-C) rising effect. The
aim of this prospective study was to investigate the association between mod-
erate wine consumption and HDL-C levels in patients who survived an acute
myocardial infarction (AMI).
Methods: From the French regional RICO survey, 920 consecutive
patients surviving an AMI were included between the 1st January and the 31st
december 2005. At one year follow-up, patients were asked to report their
wine consumption, using a questionnaire and examination of serum lipids was
performed. Associations of demographic, clinical, and lifestyle risk-factors
with HDL-C levels were assessed with multivariate analysis.
Results: Patient consuming 1-3 drink/day of wine had higher HDL-C
levels (respectively, 0.47(0.38-0.56) vs 0.43(0.35-0.53) mg/dL, (p=0.026)),
and lower CRP concentrations (2(1-5) vs 4(2-7) mg/L (p=0.01)), than non or
high-drinkers (0 or >4 drink/day). No difference was reported for triglycerides
or LDL-C levels in the two groups. In univariate analyses, CRP levels, dia-
betes, smoking and body mass index (BMI) were negatively associated with
high HDL-C (> 40 mg/dL in men and >50 mg/dL in women). In contrast,
female, physical activity and moderate wine intake were positively associated
with HDL-C. In multivariate analyses, BMI (OR (95%CI) (0.91(0.87-0.96)),
physical activity (OR(95%CI) (1.23(1.07-1.41)) and moderate wine intake
(OR(95%CI) (1.84(1.22-3.73)) were associated with high HDL-C.
Conclusion: These data suggest that a moderate wine intake is associated
with elevated levels HDL-C levels. This association may participate to the
beneficial effect of moderate wine intake on cardiovascular disease.
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Introduction: Cardiovascular diseases are the leading cause of mortality in
the western countries at the same time they are beginning to appear with
increasing frequency in developing countries. The Tunisian epidemiological
data on cardiovascular disease in the hospital environment are scarce. The aim
of this study was to evaluate the frequency of cardiovascular risk factors and
their association in patients hospitalised for coronary disease in coronary care
units at Rabta, Charles Nicolle, Habib Thameur, Tahar Maamouri, Menzel
Bourguiba and Military hospitals, over the period 1994-1998.
Patients and methods: The clinical features of 7164 patients (72.2% men
with a mean age of 59 years, 3408 myocardial infarction, 3756 unstable
angina) on hospital admission were analysed.
Results: The prevalence of hypertension (blood pressure ≥ 140/90 mmHg)
was 41.4%. There is a statistically significant difference in the prevalence of
hypertension (p<0.001) between men (33.4%), and women (62.1%). The prev-
alence of diabetes (glycemia ≥ 1.26 g/l) was 44.8%. The prevalence was
higher in women (53.3%) than in men (41.1%, p<0.001). The prevalence of
obesity (BMI ≥ 30 kg/m2) (18.8%) was higher in women (29% vs. 14.9% in
men, p<0.001). The incidence of dyslipidemia (CT > 2.5 g/l and/or TG > 1.5
g/l) was 44.9%. The percentage was higher in women (48.2%) than in men
(43.3%, P< 0.001). The prevalence of smoking was 64.3%, with a statistically
significant difference between men (84.4%) and women (12.2%). Twenty four
percent of the patients had one cardiovascular risk factor, 32% had two, 25%
had three factors and 13% had four or more factors.
Conclusion: With this risk factor profile Tunisia has to implement a
national strategy of primary prevention and heart health promotion in addition
to the efforts recently made in secondary prevention of some chronic disease
such as hypertension, diabetes and smoking.
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Purpose: To assess ten-year change in the prevalence of the metabolic syn-
drome among French subjects using the National Cholesterol Education Pro-
gram (NCEPATP III) criteria with the American Diabetes Association’s
updated definition of elevated fasting glucose (≥ 1g/l). Two definitions were
assessed, one taking into account a treatment for hypertension and for elevated
triglycerides or reduced high-density lipoprotein (HDL) cholesterol (Met2)
and the other not (Met).
Methods: Two cross-sectional representative surveys of the general popu-
lation were carried out in 1996 and 2006 in three French areas: the Urban
Community of Lille in the North, the districts of Bas-Rhin in the East and of
Haute-Garonne in the South. Inhabitants aged 35-64 years were randomly
recruited from electoral rolls after stratification on gender, 10 year-age group
and town size. Standardized sociodemographic, medical and anthropometric
data were collected and a fasted blood sample was analysed centrally. Preva-
lences in the age group 35-64 years were adjusted for the French population
of year 2000.
Results: A total of 3405 subjects in 1996 and 3554 subjects in 2006 were
included in the analyses. In both years the metabolic syndrome was more
common among men than among women and increased with age. The age-
adjusted prevalences [95% confidence interval] of Met were 26.3% [23.9-
28.7] and 18.1% [16.1-20.1] in 1996 and 23.1% [20.9-25.3] and 15.1%
[13.3-16.9] in 2006, in men and women respectively. The equivalent results
